2022 was always going to have trouble following a bonanza 2021 for medtech mergers and acquisitions. In the event, last year turned out to be the most disappointing in recent memory, at least in terms of the numbers of deals closed.

On the plus side, the total spent on buyouts was relatively healthy, and in fact surpassed that seen in three of the past 10 years. However, this was largely down to Johnson & Johnson’s $16.6bn takeover of Abiomed, which accounted for a whopping 42% of M&A spend. Without this transaction, 2022 would have looked very lacklustre indeed.

Boston Scientific is strengthening its electrophysiology and structural heart segments as it has acquired Baylis Medical Company. The Marlborough, MA-based company first announced the $1.75 billion deal in October of 2021.

With deals ranging from smaller tuck-ins to multibillion-dollar takeovers, companies are spending at a rapid rate after M&A activity came to a near halt amid the unpredictability of 2020.

Boston Scientific has agreed to acquire Baylis Medical Company for an upfront payment of $1.75 billion, adding to a growing list of 2021 acquisitions for the medtech.